- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06838286
Estudio coreano sobre seguridad y efectividad de la terapia triple OAD en diabetes tipo 2 (TRIO)
Un estudio de observación multicéntrico, prospectivo y no intervencional para evaluar la seguridad y la efectividad de la terapia triple de OAD en pacientes con mellito diabético coreano tipo 2
A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study was designed as a multicenter, prospective, non-interventional, observational study in patients with type 2 diabetes mellitus who had inadequate glycemic control with conventional combination oral hypoglycemic agents including metformin.
Participants in this study will have type 2 diabetes mellitus with insufficient glycemic control on conventional combination therapy with a DPP-4i or SGLT2i oral hypoglycemic agent, including metformin, requiring the addition of one of the following: SGLT-2i, DPP-4i, or TZD.
The 3-drug combination therapy will be prescribed to subjects based on the medical judgment of the investigator based on the licensure of SGLT-2i, DPP-4i, or TZD(efficacy, dosing, precautions for use, etc.) in a real-world practice setting and all treatment and observation, including administration of medications and laboratory tests, will be based on the medical judgment of the investigator.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Soo Lim, M.D, Ph.D.
- Número de teléfono: 82-2-6373-0773
- Correo electrónico: limsoo@snu.ac.kr
Ubicaciones de estudio
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Corea del Sur
- Reclutamiento
- Seoul National University Bundang Hospital
-
Contacto:
- Soo Lim, M.D, Ph.D.
- Número de teléfono: 1588-3369
- Correo electrónico: limsoo@snu.ac.kr
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Patients with type 2 diabetes mellitus whose glycemic control is inadequate on 2 oral hypoglycemic agents, including metformin.
Descripción
Inclusion Criteria:
- Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.
- Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.
- 7.0% ≤ HbA1c < 10.0% based on laboratory tests performed within 4 weeks of enrollment.
- Voluntarily give written informed consent after being told about the study.
Exclusion Criteria:
- Patients with type 1 diabetes and secondary diabetes.
- Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.
- Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.
- End-stage renal disease and hemodialysis patients.
- diabetic ketoacidosis Patients.
- Pregnant and lactating women.
- Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.
- Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients.
- Anyone else deemed by the investigator to be unsuitable for participation in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Metformin/DPP4i/SGLT2i
Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs. |
SGLT2 inhibitor class of drugs DPP4 inhibitor class of drugs |
|
Metformin/DPP4i/TZD
Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs. |
DPP4 inhibitor class of drugs Thiazolidinedione class of drugs |
|
Metformin/SGLT2i/DPP4i
Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs. |
SGLT2 inhibitor class of drugs DPP4 inhibitor class of drugs |
|
Metformin/SGLT2i/TZD
Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs. |
SGLT2 inhibitor class of drugs Thiazolidinedione class of drugs |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety Evaluation of Triple Combination Therapy with SGLT-2i, DPP-4i, or TZD Class Drugs, Including Metformin
Periodo de tiempo: Up to 24 months
|
Safety will be assessed based on all adverse events, laboratory test results, and vital signs collected after enrollment during the study period. |
Up to 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in HbA1c
Periodo de tiempo: 3, 6, (9), 12, 18, and 24 months
|
Evaluation of HbA1c(%) Change Compared to Baseline in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Changes in FPG
Periodo de tiempo: 3, 6, (9), 12, 18, and 24 months
|
Evaluation of FPG(mg/dL) Change Compared to Baseline in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Percentage of Subjects with HbA1c < 7.0%
Periodo de tiempo: 3, 6, (9), 12, 18, and 24 months
|
Percentage of Subjects with HbA1c < 7.0% in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Percentage of Subjects with HbA1c < 6.5%
Periodo de tiempo: 3, 6, (9), 12, 18, and 24 months
|
Percentage of Subjects with HbA1c < 6.5% in Each Combination Group |
3, 6, (9), 12, 18, and 24 months
|
|
Factors influencing HbA1c change at each time point in each combination group.
Periodo de tiempo: 3, 6, (9), 12, 18, and 24 months
|
demographics, previous hypoglycemic medications, hypoglycemic medication components and doses, duration of hypoglycemic medication, duration of disease, comorbidities, concomitant medications, etc. |
3, 6, (9), 12, 18, and 24 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in Weight
Periodo de tiempo: 3, 6, (9), 12, 18, 24 months
|
Changes in Weight(kg) Compared to Baseline in Each Combination Group |
3, 6, (9), 12, 18, 24 months
|
|
Changes in waist circumference
Periodo de tiempo: 12 and 24 months
|
Changes in waist circumference(cm) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Changes in body composition(protein mass)
Periodo de tiempo: 12 and 24 months
|
Change in total protein mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in body composition(protein mass)
Periodo de tiempo: 12 and 24 months
|
Change in protein mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in body composition(body fat)
Periodo de tiempo: 12 and 24 months
|
Change in body fat mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in body composition(mineral mass)
Periodo de tiempo: 12 and 24 months
|
Change in mineral mass from baseline in each combination group, as measured using InBody 770 or a higher model. |
12 and 24 months
|
|
Changes in Fatty Liver Index
Periodo de tiempo: 6, 12, 18, and 24 months
|
Changes in Fatty Liver Index compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in AST
Periodo de tiempo: 6, 12, 18, and 24 months
|
Changes in AST(IU/L) Compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in ALT
Periodo de tiempo: 6, 12, 18, and 24 months
|
Changes in ALT(IU/L) Compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes Platelet Levels
Periodo de tiempo: 6, 12, 18, and 24 months
|
Changes in Platelet(10^3/uL) Levels Compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in Blood Lipid Levels(Total cholesterol, LDL-C, HDL-C, TG)
Periodo de tiempo: 6, 12, 18, and 24 months
|
Change in Total cholesterol, LDL-C, HDL-C, TG(mg/dL) compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in Insulin-Related Test Levels(HOMA-IR)
Periodo de tiempo: 12 and 24 months
|
Changes in HOMA-IR compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Changes in Insulin-Related Test Levels(HOMA-β)
Periodo de tiempo: 12 and 24 months
|
Changes in HOMA-β(%) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Changes in eGFR
Periodo de tiempo: 6, 12, 18, and 24 months
|
Changes in eGFR(mL/min/1.73m2) compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Changes in UACR
Periodo de tiempo: 6, 12, 18, and 24 months
|
Changes in UACR(mg/g) compared to Baseline in Each Combination Group |
6, 12, 18, and 24 months
|
|
Change in hsCRP
Periodo de tiempo: 12 and 24 months
|
Change in hsCRP(mg/dL) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Change in ProBNP(or NT-ProBNP)
Periodo de tiempo: 12 and 24 months
|
Change in ProBNP(or NT-ProBNP)(pg/mL) compared to Baseline in Each Combination Group |
12 and 24 months
|
|
Change in PP2 Compared to Baseline in Each Combination Group
Periodo de tiempo: 3, 6, (9), 12, 18, and 24 months
|
Change in PP2(mg/dL) compared to Baseline in Each Combination Group. |
3, 6, (9), 12, 18, and 24 months
|
|
Incidence Rate of Major Adverse Cardiovascular Events(MACE)
Periodo de tiempo: 24 month
|
Incidence Rate of Major Adverse Cardiovascular Events(MACE) from Baseline to 24 Months for Each Combination Group |
24 month
|
|
Incidence Rate of Diabetic Microvascular Events
Periodo de tiempo: 24 month
|
Incidence Rate of Diabetic Microvascular Events from Baseline to 24 Months for Each Combination Group |
24 month
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades metabólicas
- Trastornos del metabolismo de la glucosa
- Diabetes mellitus
- Enfermedades Nutricionales y Metabólicas
- Diabetes Mellitus, Tipo 2
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica.
- Agentes hipoglucemiantes
- Inhibidores de proteasa
- Inhibidores de enzimas
- Acciones farmacológicas
- Acciones y usos químicos
- Inhibidores del transportador de sodio-glucosa 2
- 2,4-tiazolidinediona
- Inhibidores de la dipeptidil-peptidasa IV
Otros números de identificación del estudio
- D141_01DM2303
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .